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Abstract
However, semantics aside, we think that DXA can indeed serve as a reference standard for measuring muscle mass. Obviously,
CT and MRI are advanced techniques that can and have been used to obtain important information such as muscle size/vol-
ume and more recently amount and distribution of intra- and intermuscular adipose tissue. Also individual muscles can be
assessed separately. However, with respect to muscle mass, the comparison of DXA with CT/MRI is rather difﬁcult because
DXA and QCT/MRI measure different physical parameters
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We very much appreciate your valuable comments and your
interest in the topic raised in our paper.1 One of your main
concerns seem to be the statement at the end of our contri-
bution suggesting that ‘DXA is the gold standard for the
measurement of muscle mass’. Perhaps the term ‘gold’
could have been omitted. However, semantics aside, we
think that DXA can indeed serve as a reference standard
for measuring muscle mass as concluded in the discussion
and summarized in the abstract. Obviously, CT and MRI
are advanced techniques that can and have been used to
obtain important information such as muscle size/volume
and more recently amount and distribution of intramuscular
and intermuscular adipose tissue.2,3 Also, individual muscles
can be assessed separately. However, with respect to muscle
mass, the comparison of DXA with CT/MRI is rather difﬁcult
because DXA and QCT/MRI measure different physical
parameters.
As you correctly describe, primary outcome of DXA is lean
mass in g, of CT is muscle volume in cm3 or area in cm2 and
CT density in Hounsﬁeld units [HU] and of MRI is also muscle
volume in cm3 or area and proton density fat and water
fraction in % when using advanced Dixon sequences.4 None
of the three techniques measures muscle mass in g or muscle
density in g/cm3. CT and MRI do not even directly measure a
mass in g. Thus, from a physics point of view, none can
serve as a gold standard for any of the other twomethods, with
the exception of volume/area measurements of CT and MRI.
For the further discussion, it is important to remember
that all current deﬁnitions of sarcopenia include appendicular
lean mass but not muscle area/volume.5,6 You refer to accu-
racy validation studies with MR and CT7–10 but all evaluated
area, not mass. Correlations reported between DXA lean
mass and CT muscle area in the thigh were moderate in
young subjects (r2 = 0.74)11 and even lower in premenopausal
lean and obese women (r2 = 0.59 and r2 = 0.58, respec-
tively),12 thus a substitution of DXA by CT in the deﬁnition
of sarcopenia, i.e. of mass by volume, will be problematic.
There are indeed some studies that reportmusclemass from
CT and MRI scans.13–15 In these studies, muscle mass has been
estimated by multiplying measured muscle volume with a den-
sity of 1.06 or 1.04 g/cm3, values based on publications summa-
rized in the ICRP reference man report from 1972.16 In this
report, the proportion of fat of wet skeletal muscle in adults
is given as a range from 2.2% to 9.4%. Thus, accuracy of assum-
ing a muscle density of 1.06 or 1.04 g/cm3 is questionable if
higher degrees of muscle fat inﬁltration occur, because higher
proportions of fat will decrease density. Correlation coefﬁ-
cients of r2 ≥ 0.96 have been reported in young and elderly
healthy volunteers11,15 between muscle mass in the thigh esti-
mated with CT and fat free mass (FFM) measured by DXA but
results are likely to change in subjects with a higher amount
of intramuscular adipose tissue of let’s say greater than 10%.
Thus, these studies for a speciﬁc population serve more as a
validation of the simplifying assumptions made to obtain CT/
MRI muscle mass than a validation for DXA.
Finally, you point out only moderate correlations be-
tween longitudinal changes in lean mass and muscle vol-
ume. But with the current deﬁnitions of sarcopenia,
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wouldn’t this be an argument in favour of DXA? One could
criticize that deﬁnitions of sarcopenia inherently favour DXA
and should have been better tailored towards CT or MR
measurements in the ﬁrst place. They even use appendicu-
lar lean instead of muscle mass,17 which has been rightfully
criticized. However, the real problem is the rather poor cor-
relation of the common DXA/CT/MRI measurements with
function, which has caused the integration of functional
measurements in the deﬁnitions of sarcopenia. Thus, we
do not imply that DXA will be the gold standard for the
diagnosis of sarcopenia, which requires a functional compo-
nent. However, DXA can serve as a reference standard for
lean mass, considering the limitations described in our arti-
cle.18 Similar to osteoporosis, DXA may become the work-
horse in clinical routine of sarcopenia. CT and MRI should
be regarded as a complementary more powerful imaging
method to DXA that may improve our understanding on in-
tervention and may eventually better explain effects on
functional muscle outcome than simple lean mass or area/
volume measurements.
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